Folates and antifolates in rheumatoid arthritis

Almost all current standard treatment of care for patients with chronic inflammatory diseases such as rheumatoid arthritis (RA) includes the folate antagonist methotrexate (MTX). Despite the proven efficacy of MTX in RA treatment, it is anticipated that further improvement of antifolate-based therap...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Jansen Gerrit [verfasserIn] Weijers Karin [verfasserIn] Blits Marjolein [verfasserIn] van der Heijden Joost [verfasserIn] Gent Yoony [verfasserIn] Al Marjon [verfasserIn] van der Laken Conny [verfasserIn] Molthoff Carla [verfasserIn] Verweij Cor [verfasserIn] Voskuijl Alexandre [verfasserIn] Lems Willem [verfasserIn] Scheper Rik [verfasserIn] Peters Godefridus [verfasserIn] Ratnam Manohar [verfasserIn] Aassaraf Yehuda [verfasserIn] Dijkmans Ben [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2013

Schlagwörter:	antifolates folates rheumatoid arthritis abbreviations and enzyme codes: atic/aicartf, 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase (ec 2.1.2.3); dhfr, dihydrofolate reductase (ec 1.5.1.3); fpgs, folylpolyglutamate synthetase (ec 6.3.2.17); frα/β, folate receptor alpha/beta; gart, glycinamideribonucleotide formyltransferase (ec 2.1.2.2); ggh/fpgh, gamma-glutamyl hydrolase/folylpolyglutamate hydrolyse (ec 3.4.19.9); mthfr, methylenetetrahydrofolate reductase (ec 1.5.1.20); mtx, methotrexate; pb, peripheral blood; pcft/slc46a1, proton-coupled folate transporter; pg, polyglutamates; rfc/slc19a1, reduced folate carrier; tyms, thymidylate synthase (ec 2.1.1.45).

Übergeordnetes Werk:	In: Pteridines - De Gruyter, 2018, 24(2013), 1, Seite 21-26
Übergeordnetes Werk:	volume:24 ; year:2013 ; number:1 ; pages:21-26

Links:	Link aufrufen Link aufrufen Link aufrufen Journal toc Journal toc

DOI / URN:	10.1515/pterid-2013-0012

Katalog-ID:	DOAJ001949527

Internformat


LEADER	01000caa a22002652 4500
001	DOAJ001949527
003	DE-627
005	20230503100415.0
007	cr uuu---uuuuu
008	230225s2013 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1515/pterid-2013-0012 \|2 doi
035			\|a (DE-627)DOAJ001949527
035			\|a (DE-599)DOAJe593d5a56a1546ec9a04bf4a34f6331d
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
050		0	\|a QD901-999
100	0		\|a Jansen Gerrit \|e verfasserin \|4 aut
245	1	0	\|a Folates and antifolates in rheumatoid arthritis
264		1	\|c 2013
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a Almost all current standard treatment of care for patients with chronic inflammatory diseases such as rheumatoid arthritis (RA) includes the folate antagonist methotrexate (MTX). Despite the proven efficacy of MTX in RA treatment, it is anticipated that further improvement of antifolate-based therapies can be achieved by integrating the continuously extending knowledge of parameters underlying drug efficacy. Herein, an overview will be presented of strategies that may assist in the future design of rationalized and personalized targeted therapies with a folate antagonist. Issues that will be discussed include (i) early detection of arthritis, (ii) genomic studies of folate/MTX pathway genes for MTX response predictions, (iii) identification of MTX resistance modalities, (iv) exploration of second/third generation of antifolates which may substitute for MTX, and (v) folate (food) supplementation.
650		4	\|a antifolates
650		4	\|a folates
650		4	\|a rheumatoid arthritis
650		4	\|a abbreviations and enzyme codes: atic/aicartf, 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase (ec 2.1.2.3); dhfr, dihydrofolate reductase (ec 1.5.1.3); fpgs, folylpolyglutamate synthetase (ec 6.3.2.17); frα/β, folate receptor alpha/beta; gart, glycinamideribonucleotide formyltransferase (ec 2.1.2.2); ggh/fpgh, gamma-glutamyl hydrolase/folylpolyglutamate hydrolyse (ec 3.4.19.9); mthfr, methylenetetrahydrofolate reductase (ec 1.5.1.20); mtx, methotrexate; pb, peripheral blood; pcft/slc46a1, proton-coupled folate transporter; pg, polyglutamates; rfc/slc19a1, reduced folate carrier; tyms, thymidylate synthase (ec 2.1.1.45).
653		0	\|a Crystallography
700	0		\|a Weijers Karin \|e verfasserin \|4 aut
700	0		\|a Blits Marjolein \|e verfasserin \|4 aut
700	0		\|a van der Heijden Joost \|e verfasserin \|4 aut
700	0		\|a Gent Yoony \|e verfasserin \|4 aut
700	0		\|a Al Marjon \|e verfasserin \|4 aut
700	0		\|a van der Laken Conny \|e verfasserin \|4 aut
700	0		\|a Molthoff Carla \|e verfasserin \|4 aut
700	0		\|a Verweij Cor \|e verfasserin \|4 aut
700	0		\|a Voskuijl Alexandre \|e verfasserin \|4 aut
700	0		\|a Lems Willem \|e verfasserin \|4 aut
700	0		\|a Scheper Rik \|e verfasserin \|4 aut
700	0		\|a Peters Godefridus \|e verfasserin \|4 aut
700	0		\|a Ratnam Manohar \|e verfasserin \|4 aut
700	0		\|a Aassaraf Yehuda \|e verfasserin \|4 aut
700	0		\|a Dijkmans Ben \|e verfasserin \|4 aut
773	0	8	\|i In \|t Pteridines \|d De Gruyter, 2018 \|g 24(2013), 1, Seite 21-26 \|w (DE-627)527834432 \|w (DE-600)2279565-0 \|x 21954720 \|7 nnns
773	1	8	\|g volume:24 \|g year:2013 \|g number:1 \|g pages:21-26
856	4	0	\|u https://doi.org/10.1515/pterid-2013-0012 \|z kostenfrei
856	4	0	\|u https://doaj.org/article/e593d5a56a1546ec9a04bf4a34f6331d \|z kostenfrei
856	4	0	\|u https://doi.org/10.1515/pterid-2013-0012 \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/0933-4807 \|y Journal toc \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/2195-4720 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a SSG-OLC-PHA
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_70
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_2027
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 24 \|j 2013 \|e 1 \|h 21-26

Indexfelder

author_variant	j g jg w k wk b m bm v d h j vdhj g y gy a m am v d l c vdlc m c mc v c vc v a va l w lw s r sr p g pg r m rm a y ay d b db
matchkey_str	article:21954720:2013----::oaeadnioaeiremt
hierarchy_sort_str	2013
callnumber-subject-code	QD
publishDate	2013
allfields	10.1515/pterid-2013-0012 doi (DE-627)DOAJ001949527 (DE-599)DOAJe593d5a56a1546ec9a04bf4a34f6331d DE-627 ger DE-627 rakwb eng QD901-999 Jansen Gerrit verfasserin aut Folates and antifolates in rheumatoid arthritis 2013 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Almost all current standard treatment of care for patients with chronic inflammatory diseases such as rheumatoid arthritis (RA) includes the folate antagonist methotrexate (MTX). Despite the proven efficacy of MTX in RA treatment, it is anticipated that further improvement of antifolate-based therapies can be achieved by integrating the continuously extending knowledge of parameters underlying drug efficacy. Herein, an overview will be presented of strategies that may assist in the future design of rationalized and personalized targeted therapies with a folate antagonist. Issues that will be discussed include (i) early detection of arthritis, (ii) genomic studies of folate/MTX pathway genes for MTX response predictions, (iii) identification of MTX resistance modalities, (iv) exploration of second/third generation of antifolates which may substitute for MTX, and (v) folate (food) supplementation. antifolates folates rheumatoid arthritis abbreviations and enzyme codes: atic/aicartf, 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase (ec 2.1.2.3); dhfr, dihydrofolate reductase (ec 1.5.1.3); fpgs, folylpolyglutamate synthetase (ec 6.3.2.17); frα/β, folate receptor alpha/beta; gart, glycinamideribonucleotide formyltransferase (ec 2.1.2.2); ggh/fpgh, gamma-glutamyl hydrolase/folylpolyglutamate hydrolyse (ec 3.4.19.9); mthfr, methylenetetrahydrofolate reductase (ec 1.5.1.20); mtx, methotrexate; pb, peripheral blood; pcft/slc46a1, proton-coupled folate transporter; pg, polyglutamates; rfc/slc19a1, reduced folate carrier; tyms, thymidylate synthase (ec 2.1.1.45). Crystallography Weijers Karin verfasserin aut Blits Marjolein verfasserin aut van der Heijden Joost verfasserin aut Gent Yoony verfasserin aut Al Marjon verfasserin aut van der Laken Conny verfasserin aut Molthoff Carla verfasserin aut Verweij Cor verfasserin aut Voskuijl Alexandre verfasserin aut Lems Willem verfasserin aut Scheper Rik verfasserin aut Peters Godefridus verfasserin aut Ratnam Manohar verfasserin aut Aassaraf Yehuda verfasserin aut Dijkmans Ben verfasserin aut In Pteridines De Gruyter, 2018 24(2013), 1, Seite 21-26 (DE-627)527834432 (DE-600)2279565-0 21954720 nnns volume:24 year:2013 number:1 pages:21-26 https://doi.org/10.1515/pterid-2013-0012 kostenfrei https://doaj.org/article/e593d5a56a1546ec9a04bf4a34f6331d kostenfrei https://doi.org/10.1515/pterid-2013-0012 kostenfrei https://doaj.org/toc/0933-4807 Journal toc kostenfrei https://doaj.org/toc/2195-4720 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_2027 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 24 2013 1 21-26
spelling	10.1515/pterid-2013-0012 doi (DE-627)DOAJ001949527 (DE-599)DOAJe593d5a56a1546ec9a04bf4a34f6331d DE-627 ger DE-627 rakwb eng QD901-999 Jansen Gerrit verfasserin aut Folates and antifolates in rheumatoid arthritis 2013 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Almost all current standard treatment of care for patients with chronic inflammatory diseases such as rheumatoid arthritis (RA) includes the folate antagonist methotrexate (MTX). Despite the proven efficacy of MTX in RA treatment, it is anticipated that further improvement of antifolate-based therapies can be achieved by integrating the continuously extending knowledge of parameters underlying drug efficacy. Herein, an overview will be presented of strategies that may assist in the future design of rationalized and personalized targeted therapies with a folate antagonist. Issues that will be discussed include (i) early detection of arthritis, (ii) genomic studies of folate/MTX pathway genes for MTX response predictions, (iii) identification of MTX resistance modalities, (iv) exploration of second/third generation of antifolates which may substitute for MTX, and (v) folate (food) supplementation. antifolates folates rheumatoid arthritis abbreviations and enzyme codes: atic/aicartf, 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase (ec 2.1.2.3); dhfr, dihydrofolate reductase (ec 1.5.1.3); fpgs, folylpolyglutamate synthetase (ec 6.3.2.17); frα/β, folate receptor alpha/beta; gart, glycinamideribonucleotide formyltransferase (ec 2.1.2.2); ggh/fpgh, gamma-glutamyl hydrolase/folylpolyglutamate hydrolyse (ec 3.4.19.9); mthfr, methylenetetrahydrofolate reductase (ec 1.5.1.20); mtx, methotrexate; pb, peripheral blood; pcft/slc46a1, proton-coupled folate transporter; pg, polyglutamates; rfc/slc19a1, reduced folate carrier; tyms, thymidylate synthase (ec 2.1.1.45). Crystallography Weijers Karin verfasserin aut Blits Marjolein verfasserin aut van der Heijden Joost verfasserin aut Gent Yoony verfasserin aut Al Marjon verfasserin aut van der Laken Conny verfasserin aut Molthoff Carla verfasserin aut Verweij Cor verfasserin aut Voskuijl Alexandre verfasserin aut Lems Willem verfasserin aut Scheper Rik verfasserin aut Peters Godefridus verfasserin aut Ratnam Manohar verfasserin aut Aassaraf Yehuda verfasserin aut Dijkmans Ben verfasserin aut In Pteridines De Gruyter, 2018 24(2013), 1, Seite 21-26 (DE-627)527834432 (DE-600)2279565-0 21954720 nnns volume:24 year:2013 number:1 pages:21-26 https://doi.org/10.1515/pterid-2013-0012 kostenfrei https://doaj.org/article/e593d5a56a1546ec9a04bf4a34f6331d kostenfrei https://doi.org/10.1515/pterid-2013-0012 kostenfrei https://doaj.org/toc/0933-4807 Journal toc kostenfrei https://doaj.org/toc/2195-4720 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_2027 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 24 2013 1 21-26
allfields_unstemmed	10.1515/pterid-2013-0012 doi (DE-627)DOAJ001949527 (DE-599)DOAJe593d5a56a1546ec9a04bf4a34f6331d DE-627 ger DE-627 rakwb eng QD901-999 Jansen Gerrit verfasserin aut Folates and antifolates in rheumatoid arthritis 2013 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Almost all current standard treatment of care for patients with chronic inflammatory diseases such as rheumatoid arthritis (RA) includes the folate antagonist methotrexate (MTX). Despite the proven efficacy of MTX in RA treatment, it is anticipated that further improvement of antifolate-based therapies can be achieved by integrating the continuously extending knowledge of parameters underlying drug efficacy. Herein, an overview will be presented of strategies that may assist in the future design of rationalized and personalized targeted therapies with a folate antagonist. Issues that will be discussed include (i) early detection of arthritis, (ii) genomic studies of folate/MTX pathway genes for MTX response predictions, (iii) identification of MTX resistance modalities, (iv) exploration of second/third generation of antifolates which may substitute for MTX, and (v) folate (food) supplementation. antifolates folates rheumatoid arthritis abbreviations and enzyme codes: atic/aicartf, 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase (ec 2.1.2.3); dhfr, dihydrofolate reductase (ec 1.5.1.3); fpgs, folylpolyglutamate synthetase (ec 6.3.2.17); frα/β, folate receptor alpha/beta; gart, glycinamideribonucleotide formyltransferase (ec 2.1.2.2); ggh/fpgh, gamma-glutamyl hydrolase/folylpolyglutamate hydrolyse (ec 3.4.19.9); mthfr, methylenetetrahydrofolate reductase (ec 1.5.1.20); mtx, methotrexate; pb, peripheral blood; pcft/slc46a1, proton-coupled folate transporter; pg, polyglutamates; rfc/slc19a1, reduced folate carrier; tyms, thymidylate synthase (ec 2.1.1.45). Crystallography Weijers Karin verfasserin aut Blits Marjolein verfasserin aut van der Heijden Joost verfasserin aut Gent Yoony verfasserin aut Al Marjon verfasserin aut van der Laken Conny verfasserin aut Molthoff Carla verfasserin aut Verweij Cor verfasserin aut Voskuijl Alexandre verfasserin aut Lems Willem verfasserin aut Scheper Rik verfasserin aut Peters Godefridus verfasserin aut Ratnam Manohar verfasserin aut Aassaraf Yehuda verfasserin aut Dijkmans Ben verfasserin aut In Pteridines De Gruyter, 2018 24(2013), 1, Seite 21-26 (DE-627)527834432 (DE-600)2279565-0 21954720 nnns volume:24 year:2013 number:1 pages:21-26 https://doi.org/10.1515/pterid-2013-0012 kostenfrei https://doaj.org/article/e593d5a56a1546ec9a04bf4a34f6331d kostenfrei https://doi.org/10.1515/pterid-2013-0012 kostenfrei https://doaj.org/toc/0933-4807 Journal toc kostenfrei https://doaj.org/toc/2195-4720 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_2027 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 24 2013 1 21-26
allfieldsGer	10.1515/pterid-2013-0012 doi (DE-627)DOAJ001949527 (DE-599)DOAJe593d5a56a1546ec9a04bf4a34f6331d DE-627 ger DE-627 rakwb eng QD901-999 Jansen Gerrit verfasserin aut Folates and antifolates in rheumatoid arthritis 2013 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Almost all current standard treatment of care for patients with chronic inflammatory diseases such as rheumatoid arthritis (RA) includes the folate antagonist methotrexate (MTX). Despite the proven efficacy of MTX in RA treatment, it is anticipated that further improvement of antifolate-based therapies can be achieved by integrating the continuously extending knowledge of parameters underlying drug efficacy. Herein, an overview will be presented of strategies that may assist in the future design of rationalized and personalized targeted therapies with a folate antagonist. Issues that will be discussed include (i) early detection of arthritis, (ii) genomic studies of folate/MTX pathway genes for MTX response predictions, (iii) identification of MTX resistance modalities, (iv) exploration of second/third generation of antifolates which may substitute for MTX, and (v) folate (food) supplementation. antifolates folates rheumatoid arthritis abbreviations and enzyme codes: atic/aicartf, 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase (ec 2.1.2.3); dhfr, dihydrofolate reductase (ec 1.5.1.3); fpgs, folylpolyglutamate synthetase (ec 6.3.2.17); frα/β, folate receptor alpha/beta; gart, glycinamideribonucleotide formyltransferase (ec 2.1.2.2); ggh/fpgh, gamma-glutamyl hydrolase/folylpolyglutamate hydrolyse (ec 3.4.19.9); mthfr, methylenetetrahydrofolate reductase (ec 1.5.1.20); mtx, methotrexate; pb, peripheral blood; pcft/slc46a1, proton-coupled folate transporter; pg, polyglutamates; rfc/slc19a1, reduced folate carrier; tyms, thymidylate synthase (ec 2.1.1.45). Crystallography Weijers Karin verfasserin aut Blits Marjolein verfasserin aut van der Heijden Joost verfasserin aut Gent Yoony verfasserin aut Al Marjon verfasserin aut van der Laken Conny verfasserin aut Molthoff Carla verfasserin aut Verweij Cor verfasserin aut Voskuijl Alexandre verfasserin aut Lems Willem verfasserin aut Scheper Rik verfasserin aut Peters Godefridus verfasserin aut Ratnam Manohar verfasserin aut Aassaraf Yehuda verfasserin aut Dijkmans Ben verfasserin aut In Pteridines De Gruyter, 2018 24(2013), 1, Seite 21-26 (DE-627)527834432 (DE-600)2279565-0 21954720 nnns volume:24 year:2013 number:1 pages:21-26 https://doi.org/10.1515/pterid-2013-0012 kostenfrei https://doaj.org/article/e593d5a56a1546ec9a04bf4a34f6331d kostenfrei https://doi.org/10.1515/pterid-2013-0012 kostenfrei https://doaj.org/toc/0933-4807 Journal toc kostenfrei https://doaj.org/toc/2195-4720 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_2027 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 24 2013 1 21-26
allfieldsSound	10.1515/pterid-2013-0012 doi (DE-627)DOAJ001949527 (DE-599)DOAJe593d5a56a1546ec9a04bf4a34f6331d DE-627 ger DE-627 rakwb eng QD901-999 Jansen Gerrit verfasserin aut Folates and antifolates in rheumatoid arthritis 2013 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Almost all current standard treatment of care for patients with chronic inflammatory diseases such as rheumatoid arthritis (RA) includes the folate antagonist methotrexate (MTX). Despite the proven efficacy of MTX in RA treatment, it is anticipated that further improvement of antifolate-based therapies can be achieved by integrating the continuously extending knowledge of parameters underlying drug efficacy. Herein, an overview will be presented of strategies that may assist in the future design of rationalized and personalized targeted therapies with a folate antagonist. Issues that will be discussed include (i) early detection of arthritis, (ii) genomic studies of folate/MTX pathway genes for MTX response predictions, (iii) identification of MTX resistance modalities, (iv) exploration of second/third generation of antifolates which may substitute for MTX, and (v) folate (food) supplementation. antifolates folates rheumatoid arthritis abbreviations and enzyme codes: atic/aicartf, 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase (ec 2.1.2.3); dhfr, dihydrofolate reductase (ec 1.5.1.3); fpgs, folylpolyglutamate synthetase (ec 6.3.2.17); frα/β, folate receptor alpha/beta; gart, glycinamideribonucleotide formyltransferase (ec 2.1.2.2); ggh/fpgh, gamma-glutamyl hydrolase/folylpolyglutamate hydrolyse (ec 3.4.19.9); mthfr, methylenetetrahydrofolate reductase (ec 1.5.1.20); mtx, methotrexate; pb, peripheral blood; pcft/slc46a1, proton-coupled folate transporter; pg, polyglutamates; rfc/slc19a1, reduced folate carrier; tyms, thymidylate synthase (ec 2.1.1.45). Crystallography Weijers Karin verfasserin aut Blits Marjolein verfasserin aut van der Heijden Joost verfasserin aut Gent Yoony verfasserin aut Al Marjon verfasserin aut van der Laken Conny verfasserin aut Molthoff Carla verfasserin aut Verweij Cor verfasserin aut Voskuijl Alexandre verfasserin aut Lems Willem verfasserin aut Scheper Rik verfasserin aut Peters Godefridus verfasserin aut Ratnam Manohar verfasserin aut Aassaraf Yehuda verfasserin aut Dijkmans Ben verfasserin aut In Pteridines De Gruyter, 2018 24(2013), 1, Seite 21-26 (DE-627)527834432 (DE-600)2279565-0 21954720 nnns volume:24 year:2013 number:1 pages:21-26 https://doi.org/10.1515/pterid-2013-0012 kostenfrei https://doaj.org/article/e593d5a56a1546ec9a04bf4a34f6331d kostenfrei https://doi.org/10.1515/pterid-2013-0012 kostenfrei https://doaj.org/toc/0933-4807 Journal toc kostenfrei https://doaj.org/toc/2195-4720 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_2027 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 24 2013 1 21-26
language	English
source	In Pteridines 24(2013), 1, Seite 21-26 volume:24 year:2013 number:1 pages:21-26
sourceStr	In Pteridines 24(2013), 1, Seite 21-26 volume:24 year:2013 number:1 pages:21-26
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	antifolates folates rheumatoid arthritis abbreviations and enzyme codes: atic/aicartf, 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase (ec 2.1.2.3); dhfr, dihydrofolate reductase (ec 1.5.1.3); fpgs, folylpolyglutamate synthetase (ec 6.3.2.17); frα/β, folate receptor alpha/beta; gart, glycinamideribonucleotide formyltransferase (ec 2.1.2.2); ggh/fpgh, gamma-glutamyl hydrolase/folylpolyglutamate hydrolyse (ec 3.4.19.9); mthfr, methylenetetrahydrofolate reductase (ec 1.5.1.20); mtx, methotrexate; pb, peripheral blood; pcft/slc46a1, proton-coupled folate transporter; pg, polyglutamates; rfc/slc19a1, reduced folate carrier; tyms, thymidylate synthase (ec 2.1.1.45). Crystallography
isfreeaccess_bool	true
container_title	Pteridines
authorswithroles_txt_mv	Jansen Gerrit @@aut@@ Weijers Karin @@aut@@ Blits Marjolein @@aut@@ van der Heijden Joost @@aut@@ Gent Yoony @@aut@@ Al Marjon @@aut@@ van der Laken Conny @@aut@@ Molthoff Carla @@aut@@ Verweij Cor @@aut@@ Voskuijl Alexandre @@aut@@ Lems Willem @@aut@@ Scheper Rik @@aut@@ Peters Godefridus @@aut@@ Ratnam Manohar @@aut@@ Aassaraf Yehuda @@aut@@ Dijkmans Ben @@aut@@
publishDateDaySort_date	2013-01-01T00:00:00Z
hierarchy_top_id	527834432
id	DOAJ001949527
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ001949527</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230503100415.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230225s2013 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1515/pterid-2013-0012</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ001949527</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJe593d5a56a1546ec9a04bf4a34f6331d</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">QD901-999</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Jansen Gerrit</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Folates and antifolates in rheumatoid arthritis</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2013</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Almost all current standard treatment of care for patients with chronic inflammatory diseases such as rheumatoid arthritis (RA) includes the folate antagonist methotrexate (MTX). Despite the proven efficacy of MTX in RA treatment, it is anticipated that further improvement of antifolate-based therapies can be achieved by integrating the continuously extending knowledge of parameters underlying drug efficacy. Herein, an overview will be presented of strategies that may assist in the future design of rationalized and personalized targeted therapies with a folate antagonist. Issues that will be discussed include (i) early detection of arthritis, (ii) genomic studies of folate/MTX pathway genes for MTX response predictions, (iii) identification of MTX resistance modalities, (iv) exploration of second/third generation of antifolates which may substitute for MTX, and (v) folate (food) supplementation.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">antifolates</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">folates</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">rheumatoid arthritis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">abbreviations and enzyme codes: atic/aicartf, 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase (ec 2.1.2.3); dhfr, dihydrofolate reductase (ec 1.5.1.3); fpgs, folylpolyglutamate synthetase (ec 6.3.2.17); frα/β, folate receptor alpha/beta; gart, glycinamideribonucleotide formyltransferase (ec 2.1.2.2); ggh/fpgh, gamma-glutamyl hydrolase/folylpolyglutamate hydrolyse (ec 3.4.19.9); mthfr, methylenetetrahydrofolate reductase (ec 1.5.1.20); mtx, methotrexate; pb, peripheral blood; pcft/slc46a1, proton-coupled folate transporter; pg, polyglutamates; rfc/slc19a1, reduced folate carrier; tyms, thymidylate synthase (ec 2.1.1.45).</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Crystallography</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Weijers Karin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Blits Marjolein</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">van der Heijden Joost</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Gent Yoony</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Al Marjon</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">van der Laken Conny</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Molthoff Carla</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Verweij Cor</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Voskuijl Alexandre</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Lems Willem</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Scheper Rik</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Peters Godefridus</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ratnam Manohar</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Aassaraf Yehuda</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Dijkmans Ben</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Pteridines</subfield><subfield code="d">De Gruyter, 2018</subfield><subfield code="g">24(2013), 1, Seite 21-26</subfield><subfield code="w">(DE-627)527834432</subfield><subfield code="w">(DE-600)2279565-0</subfield><subfield code="x">21954720</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:24</subfield><subfield code="g">year:2013</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:21-26</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1515/pterid-2013-0012</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/e593d5a56a1546ec9a04bf4a34f6331d</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1515/pterid-2013-0012</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/0933-4807</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2195-4720</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2027</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">24</subfield><subfield code="j">2013</subfield><subfield code="e">1</subfield><subfield code="h">21-26</subfield></datafield></record></collection>
callnumber-first	Q - Science
author	Jansen Gerrit
spellingShingle	Jansen Gerrit misc QD901-999 misc antifolates misc folates misc rheumatoid arthritis misc abbreviations and enzyme codes: atic/aicartf, 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase (ec 2.1.2.3); dhfr, dihydrofolate reductase (ec 1.5.1.3); fpgs, folylpolyglutamate synthetase (ec 6.3.2.17); frα/β, folate receptor alpha/beta; gart, glycinamideribonucleotide formyltransferase (ec 2.1.2.2); ggh/fpgh, gamma-glutamyl hydrolase/folylpolyglutamate hydrolyse (ec 3.4.19.9); mthfr, methylenetetrahydrofolate reductase (ec 1.5.1.20); mtx, methotrexate; pb, peripheral blood; pcft/slc46a1, proton-coupled folate transporter; pg, polyglutamates; rfc/slc19a1, reduced folate carrier; tyms, thymidylate synthase (ec 2.1.1.45). misc Crystallography Folates and antifolates in rheumatoid arthritis
authorStr	Jansen Gerrit
ppnlink_with_tag_str_mv	@@773@@(DE-627)527834432
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut
collection	DOAJ
remote_str	true
callnumber-label	QD901-999
illustrated	Not Illustrated
issn	21954720
topic_title	QD901-999 Folates and antifolates in rheumatoid arthritis antifolates folates rheumatoid arthritis abbreviations and enzyme codes: atic/aicartf, 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase (ec 2.1.2.3); dhfr, dihydrofolate reductase (ec 1.5.1.3); fpgs, folylpolyglutamate synthetase (ec 6.3.2.17); frα/β, folate receptor alpha/beta; gart, glycinamideribonucleotide formyltransferase (ec 2.1.2.2); ggh/fpgh, gamma-glutamyl hydrolase/folylpolyglutamate hydrolyse (ec 3.4.19.9); mthfr, methylenetetrahydrofolate reductase (ec 1.5.1.20); mtx, methotrexate; pb, peripheral blood; pcft/slc46a1, proton-coupled folate transporter; pg, polyglutamates; rfc/slc19a1, reduced folate carrier; tyms, thymidylate synthase (ec 2.1.1.45)
topic	misc QD901-999 misc antifolates misc folates misc rheumatoid arthritis misc abbreviations and enzyme codes: atic/aicartf, 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase (ec 2.1.2.3); dhfr, dihydrofolate reductase (ec 1.5.1.3); fpgs, folylpolyglutamate synthetase (ec 6.3.2.17); frα/β, folate receptor alpha/beta; gart, glycinamideribonucleotide formyltransferase (ec 2.1.2.2); ggh/fpgh, gamma-glutamyl hydrolase/folylpolyglutamate hydrolyse (ec 3.4.19.9); mthfr, methylenetetrahydrofolate reductase (ec 1.5.1.20); mtx, methotrexate; pb, peripheral blood; pcft/slc46a1, proton-coupled folate transporter; pg, polyglutamates; rfc/slc19a1, reduced folate carrier; tyms, thymidylate synthase (ec 2.1.1.45). misc Crystallography
topic_unstemmed	misc QD901-999 misc antifolates misc folates misc rheumatoid arthritis misc abbreviations and enzyme codes: atic/aicartf, 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase (ec 2.1.2.3); dhfr, dihydrofolate reductase (ec 1.5.1.3); fpgs, folylpolyglutamate synthetase (ec 6.3.2.17); frα/β, folate receptor alpha/beta; gart, glycinamideribonucleotide formyltransferase (ec 2.1.2.2); ggh/fpgh, gamma-glutamyl hydrolase/folylpolyglutamate hydrolyse (ec 3.4.19.9); mthfr, methylenetetrahydrofolate reductase (ec 1.5.1.20); mtx, methotrexate; pb, peripheral blood; pcft/slc46a1, proton-coupled folate transporter; pg, polyglutamates; rfc/slc19a1, reduced folate carrier; tyms, thymidylate synthase (ec 2.1.1.45). misc Crystallography
topic_browse	misc QD901-999 misc antifolates misc folates misc rheumatoid arthritis misc abbreviations and enzyme codes: atic/aicartf, 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase (ec 2.1.2.3); dhfr, dihydrofolate reductase (ec 1.5.1.3); fpgs, folylpolyglutamate synthetase (ec 6.3.2.17); frα/β, folate receptor alpha/beta; gart, glycinamideribonucleotide formyltransferase (ec 2.1.2.2); ggh/fpgh, gamma-glutamyl hydrolase/folylpolyglutamate hydrolyse (ec 3.4.19.9); mthfr, methylenetetrahydrofolate reductase (ec 1.5.1.20); mtx, methotrexate; pb, peripheral blood; pcft/slc46a1, proton-coupled folate transporter; pg, polyglutamates; rfc/slc19a1, reduced folate carrier; tyms, thymidylate synthase (ec 2.1.1.45). misc Crystallography
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Pteridines
hierarchy_parent_id	527834432
hierarchy_top_title	Pteridines
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)527834432 (DE-600)2279565-0
title	Folates and antifolates in rheumatoid arthritis
ctrlnum	(DE-627)DOAJ001949527 (DE-599)DOAJe593d5a56a1546ec9a04bf4a34f6331d
title_full	Folates and antifolates in rheumatoid arthritis
author_sort	Jansen Gerrit
journal	Pteridines
journalStr	Pteridines
callnumber-first-code	Q
lang_code	eng
isOA_bool	true
recordtype	marc
publishDateSort	2013
contenttype_str_mv	txt
container_start_page	21
author_browse	Jansen Gerrit Weijers Karin Blits Marjolein van der Heijden Joost Gent Yoony Al Marjon van der Laken Conny Molthoff Carla Verweij Cor Voskuijl Alexandre Lems Willem Scheper Rik Peters Godefridus Ratnam Manohar Aassaraf Yehuda Dijkmans Ben
container_volume	24
class	QD901-999
format_se	Elektronische Aufsätze
author-letter	Jansen Gerrit
doi_str_mv	10.1515/pterid-2013-0012
author2-role	verfasserin
title_sort	folates and antifolates in rheumatoid arthritis
callnumber	QD901-999
title_auth	Folates and antifolates in rheumatoid arthritis
abstract	Almost all current standard treatment of care for patients with chronic inflammatory diseases such as rheumatoid arthritis (RA) includes the folate antagonist methotrexate (MTX). Despite the proven efficacy of MTX in RA treatment, it is anticipated that further improvement of antifolate-based therapies can be achieved by integrating the continuously extending knowledge of parameters underlying drug efficacy. Herein, an overview will be presented of strategies that may assist in the future design of rationalized and personalized targeted therapies with a folate antagonist. Issues that will be discussed include (i) early detection of arthritis, (ii) genomic studies of folate/MTX pathway genes for MTX response predictions, (iii) identification of MTX resistance modalities, (iv) exploration of second/third generation of antifolates which may substitute for MTX, and (v) folate (food) supplementation.
abstractGer	Almost all current standard treatment of care for patients with chronic inflammatory diseases such as rheumatoid arthritis (RA) includes the folate antagonist methotrexate (MTX). Despite the proven efficacy of MTX in RA treatment, it is anticipated that further improvement of antifolate-based therapies can be achieved by integrating the continuously extending knowledge of parameters underlying drug efficacy. Herein, an overview will be presented of strategies that may assist in the future design of rationalized and personalized targeted therapies with a folate antagonist. Issues that will be discussed include (i) early detection of arthritis, (ii) genomic studies of folate/MTX pathway genes for MTX response predictions, (iii) identification of MTX resistance modalities, (iv) exploration of second/third generation of antifolates which may substitute for MTX, and (v) folate (food) supplementation.
abstract_unstemmed	Almost all current standard treatment of care for patients with chronic inflammatory diseases such as rheumatoid arthritis (RA) includes the folate antagonist methotrexate (MTX). Despite the proven efficacy of MTX in RA treatment, it is anticipated that further improvement of antifolate-based therapies can be achieved by integrating the continuously extending knowledge of parameters underlying drug efficacy. Herein, an overview will be presented of strategies that may assist in the future design of rationalized and personalized targeted therapies with a folate antagonist. Issues that will be discussed include (i) early detection of arthritis, (ii) genomic studies of folate/MTX pathway genes for MTX response predictions, (iii) identification of MTX resistance modalities, (iv) exploration of second/third generation of antifolates which may substitute for MTX, and (v) folate (food) supplementation.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_2027 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
container_issue	1
title_short	Folates and antifolates in rheumatoid arthritis
url	https://doi.org/10.1515/pterid-2013-0012 https://doaj.org/article/e593d5a56a1546ec9a04bf4a34f6331d https://doaj.org/toc/0933-4807 https://doaj.org/toc/2195-4720
remote_bool	true
author2	Weijers Karin Blits Marjolein van der Heijden Joost Gent Yoony Al Marjon van der Laken Conny Molthoff Carla Verweij Cor Voskuijl Alexandre Lems Willem Scheper Rik Peters Godefridus Ratnam Manohar Aassaraf Yehuda Dijkmans Ben
author2Str	Weijers Karin Blits Marjolein van der Heijden Joost Gent Yoony Al Marjon van der Laken Conny Molthoff Carla Verweij Cor Voskuijl Alexandre Lems Willem Scheper Rik Peters Godefridus Ratnam Manohar Aassaraf Yehuda Dijkmans Ben
ppnlink	527834432
callnumber-subject	QD - Chemistry
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.1515/pterid-2013-0012
callnumber-a	QD901-999
up_date	2024-07-03T23:13:03.946Z
_version_	1803601454245609473
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ001949527</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230503100415.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230225s2013 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1515/pterid-2013-0012</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ001949527</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJe593d5a56a1546ec9a04bf4a34f6331d</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">QD901-999</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Jansen Gerrit</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Folates and antifolates in rheumatoid arthritis</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2013</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Almost all current standard treatment of care for patients with chronic inflammatory diseases such as rheumatoid arthritis (RA) includes the folate antagonist methotrexate (MTX). Despite the proven efficacy of MTX in RA treatment, it is anticipated that further improvement of antifolate-based therapies can be achieved by integrating the continuously extending knowledge of parameters underlying drug efficacy. Herein, an overview will be presented of strategies that may assist in the future design of rationalized and personalized targeted therapies with a folate antagonist. Issues that will be discussed include (i) early detection of arthritis, (ii) genomic studies of folate/MTX pathway genes for MTX response predictions, (iii) identification of MTX resistance modalities, (iv) exploration of second/third generation of antifolates which may substitute for MTX, and (v) folate (food) supplementation.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">antifolates</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">folates</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">rheumatoid arthritis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">abbreviations and enzyme codes: atic/aicartf, 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase (ec 2.1.2.3); dhfr, dihydrofolate reductase (ec 1.5.1.3); fpgs, folylpolyglutamate synthetase (ec 6.3.2.17); frα/β, folate receptor alpha/beta; gart, glycinamideribonucleotide formyltransferase (ec 2.1.2.2); ggh/fpgh, gamma-glutamyl hydrolase/folylpolyglutamate hydrolyse (ec 3.4.19.9); mthfr, methylenetetrahydrofolate reductase (ec 1.5.1.20); mtx, methotrexate; pb, peripheral blood; pcft/slc46a1, proton-coupled folate transporter; pg, polyglutamates; rfc/slc19a1, reduced folate carrier; tyms, thymidylate synthase (ec 2.1.1.45).</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Crystallography</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Weijers Karin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Blits Marjolein</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">van der Heijden Joost</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Gent Yoony</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Al Marjon</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">van der Laken Conny</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Molthoff Carla</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Verweij Cor</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Voskuijl Alexandre</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Lems Willem</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Scheper Rik</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Peters Godefridus</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ratnam Manohar</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Aassaraf Yehuda</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Dijkmans Ben</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Pteridines</subfield><subfield code="d">De Gruyter, 2018</subfield><subfield code="g">24(2013), 1, Seite 21-26</subfield><subfield code="w">(DE-627)527834432</subfield><subfield code="w">(DE-600)2279565-0</subfield><subfield code="x">21954720</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:24</subfield><subfield code="g">year:2013</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:21-26</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1515/pterid-2013-0012</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/e593d5a56a1546ec9a04bf4a34f6331d</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1515/pterid-2013-0012</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/0933-4807</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2195-4720</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2027</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">24</subfield><subfield code="j">2013</subfield><subfield code="e">1</subfield><subfield code="h">21-26</subfield></datafield></record></collection>
score	7.4001083

Nicht das Richtige dabei?

Schreiben Sie uns!

Folates and antifolates in rheumatoid arthritis

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?